3.4.17.21 22Rv1 cell - 708256 3.4.17.21 astrocyte - 669923, 669962, 670363, 670397, 701258, 731257, 752980 3.4.17.21 astrocyte the level of glutamate carboxypeptidase II protein (GCPII) is regulated by valproic acid, a histone deacetylase (HDAC) inhibitor, through acetylation of lysine residue in the GCPII protein in human astrocytes, U-87MG 752648 3.4.17.21 blood - 697394 3.4.17.21 blood plasma the enzyme is present in human blood, and its concentration within a healthy population varies between 1.3 and 17.2 ng/ml 755286 3.4.17.21 brain - -, 137210, 137217, 137221, 137222, 137223, 137224, 137225, 655290, 656468, 667114, 668408, 669943, 669962, 670363, 670857, 696330, 701206, 701258, 707124, 709605 3.4.17.21 brain amygdala, caudate-putamen, central gray, dorsal raphe, globus pallidus, hippocampus, hypothalamus, locus coerulus, medial and lateral geniculate, olfactory bulb, periaqueductal gray, solitary nucleus, spinal trigeminal nucleus, substantia nigra, superior colliculus, thalamus, corpus callosum, fornix, habenular commissure, solitary tract, stria medularis, stria therminalis 137229 3.4.17.21 brain considerably increased in prostate carcinoma 753584 3.4.17.21 brain decreased gene expression and activity in the frontal and temporal lobe, the dorsolateral prefrontal cortex, and the hippocampus in schizophrenia, overview, no intracellular activity in pyramidal cells and their dendrites 670397 3.4.17.21 brain especially midbrain and cerebellum, quantitative detection of GCPII content in the brain by labeling with [125I]-N-[N-((S)-1,3-dicarboxypropyl)carbamoyl]-S-3-iodo-L-tyrosine is a potent antagonist of the enzyme activity 670406 3.4.17.21 brain forebrain 137216 3.4.17.21 brain GCPII 669923 3.4.17.21 brain high expression 753584 3.4.17.21 brain highest in cerebellum, lowest in telencephalic structures 137228 3.4.17.21 brain hippocampus 137215 3.4.17.21 brain regional distribution 137227 3.4.17.21 breast quantitative expression analysis 670740 3.4.17.21 cell culture - 668484 3.4.17.21 cell culture cerebral ischemia cell culture model 669776 3.4.17.21 cell culture cortical cells 656609 3.4.17.21 central nervous system - 668106, 670363, 670817 3.4.17.21 cerebellum - 669923 3.4.17.21 cerebellum glomeruli in the cerebellum 701258 3.4.17.21 cerebral cortex cortical cells dissociated in cell culture 656609 3.4.17.21 cerebrospinal fluid ventricular, lumbar, and subarachnoid 707124 3.4.17.21 colorectal cancer cell primary cancer 708666 3.4.17.21 CWR22Rv1 cell - 668154, 710458 3.4.17.21 DU-145 cell - 709812 3.4.17.21 DU-145 cell low expression level 708256 3.4.17.21 DU-145 cell very low enzyme expression level 670740 3.4.17.21 entorhinal cortex - 701206 3.4.17.21 epithelium - 668154, 668866, 670219 3.4.17.21 epithelium prostate gland 709812 3.4.17.21 ganglion dorsal root ganglia 698502 3.4.17.21 gastric cancer cell PSMA is expressed in the neovasculature of multiple nonprostatic solid tumors, it shows a unique expression pattern limited to tumor-associated endothelial cells. Expression in liver metastasis from colorectal cancers and lymph node metastasis from colorectal cancers 708666 3.4.17.21 glial cell - 667114, 670363, 707124 3.4.17.21 glial cell GCPII, not GCPIII 669923 3.4.17.21 hippocampus - 669923, 669943, 670363, 670397 3.4.17.21 hippocampus CA3 region, dorsal 669962 3.4.17.21 hippocampus hippocampus-stratum lucidum 701206 3.4.17.21 kidney - 137228, 670817, 696330, 701206 3.4.17.21 kidney high expression 753584 3.4.17.21 kidney kidney cortex, specifically in the brush border of proximal convoluted tubules 137229 3.4.17.21 liver - 701206, 732312 3.4.17.21 LNCaP cell - 656377, 683948, 707973, 707988, 708256, 709440, 709648, 709808, 709812, 710006, 710007, 710458, 710460 3.4.17.21 LNCaP cell lymph node metastasis prostate cancer cells 708325 3.4.17.21 LNCaP cell originating from a prostate cancer lymph node metastasis 668154, 670219 3.4.17.21 LNCaP cell prostate cancer cell line 656634 3.4.17.21 LNCaP cell quantitative expression analysis 670740 3.4.17.21 LNCaP cell subline C4-2 709649 3.4.17.21 lung GCPIII 669923 3.4.17.21 MDA-PCa-2b cell - 710458 3.4.17.21 medial temporal lobe - 701206 3.4.17.21 additional information analysis of enzyme expression in prostate tissue during carcinoma development 668866 3.4.17.21 additional information no activity detected in mouse prostate 753584 3.4.17.21 additional information no activity in PC-3 cells 709440, 709648 3.4.17.21 additional information no activity in the PSMA-negative prostate cancer cell line DU 145 709649 3.4.17.21 additional information PC-3 cells are PSMA-negative 710460 3.4.17.21 additional information PC-3 cells lack PSMA 707988 3.4.17.21 additional information PSMA expression analysis, overview 710458 3.4.17.21 additional information quantitative PSMA expression analysis in cancer cell lines and tissues, overview 708256 3.4.17.21 additional information quantitative PSMA expression analysis in cancer cells, overview 708666 3.4.17.21 additional information tissue distribution of GCPIII activity and expression, overview 669923 3.4.17.21 nerve - 669932 3.4.17.21 nervous system - 699452 3.4.17.21 nervous system GCPII 708479 3.4.17.21 neuron - 668484, 668486, 669962, 670363, 670397 3.4.17.21 neuron CA3 pyramidal neuron 669943 3.4.17.21 nonmyelinating Schwann cell - 707124 3.4.17.21 ovary GCPIII 669923 3.4.17.21 PC-3 cell very low enzyme expression level 670740 3.4.17.21 peripheral nerve - 137221 3.4.17.21 peripheral nervous system - 670363, 670817, 698502 3.4.17.21 phrenic nerve - 137221 3.4.17.21 plasma - 732852 3.4.17.21 prefrontal cortex - 701206 3.4.17.21 prefrontal cortex withdrawal of 3,4-methylenedioxypyrovalerone reduces expression of glutamate carboxypeptidase II in the prefrontal cortex 755361 3.4.17.21 prostate - 669506, 696330, 701206, 707973, 709648 3.4.17.21 prostate epithelial cells 670219 3.4.17.21 prostate GCPII 708479 3.4.17.21 prostate parenchym 683948 3.4.17.21 prostate cancer cell - 667114, 668408, 670219, 670685, 670794, 708325, 709440, 709812, 710006, 710007, 710358, 710457, 710458 3.4.17.21 prostate cancer cell high enzyme expression level 708666 3.4.17.21 prostate cancer cell high PSMA expression level, overexpression in advanced stage prostate adenocarcinomas. PSMA expression analysis and distribution pattern of PSMA in primary and metastatic tumors, immunohistochemic detection, overview 710204 3.4.17.21 prostate cancer cell highly up-regulated PSMA 707988 3.4.17.21 prostate cancer cell overexpression of the enzyme in prostate cancer 668154 3.4.17.21 prostate cancer cell prostate-specific membrane antigen, PSMA 670363 3.4.17.21 prostate cancer cell PSMA is a transmembrane protein commonly found on the surface of late-stage and metastatic prostate cancer 709648 3.4.17.21 prostate cancer cell line prostate cancer cell line 668866 3.4.17.21 prostate carcinoma cell - 669595 3.4.17.21 prostate carcinoma cell overexpression of PMSA 669506 3.4.17.21 prostate epithelium - 707988, 710204 3.4.17.21 prostate gland - 137211, 137212, 137213, 669595, 670794, 753584 3.4.17.21 prostate gland epithelial cells 668154 3.4.17.21 prostate gland highly expressed, might be associated with prostate cancer progression 755286 3.4.17.21 prostate gland prostate form of the enzyme is termed prostate-specific membrane antigen 667114, 670817 3.4.17.21 prostate gland prostate-specific membrane antigen, PSMA 670363 3.4.17.21 prostate gland prostrate carcinoma cell line LNCaP 137218, 137219, 137226, 137230 3.4.17.21 prostate gland quantitative expression analysis 670740 3.4.17.21 prostate gland cancer cell considerably increased in prostate carcinoma 753584 3.4.17.21 prostate gland cancer cell lymph node metastasis, PSMA is highly expressed in 100% of the lymph node metastases originating from prostate cancer 710456 3.4.17.21 prostate gland cancer cell prostatic adenocarcinoma and intraepithelial neoplasia 668866 3.4.17.21 prostate gland epithelium high expression level 708256 3.4.17.21 salivary gland high expression 753584 3.4.17.21 Schwann cell - 698502 3.4.17.21 sciatic nerve - 137221, 698502 3.4.17.21 sciatic nerve expressed during late embryonal and early postnatal development. During the first prenatal week the enzyme is downregulated in myelinating Schwann cells while the total enzyme concentrations in the nerves are transiently increased 137220 3.4.17.21 sciatic nerve modeling 668484 3.4.17.21 serum higher level in patients with prostrate cancer, lower levels in healthy male donors 137214 3.4.17.21 small intestine - 670817, 696330, 701206 3.4.17.21 small intestine GCPII 708479 3.4.17.21 small intestine membrane brush border 667114 3.4.17.21 spinal cord - 655503, 668486, 669923, 701206 3.4.17.21 spinal ganglion - 137221 3.4.17.21 spleen - 701206 3.4.17.21 superior cervical ganglion - 137221 3.4.17.21 testis GCPIII 669923 3.4.17.21 trachea - 701206 3.4.17.21 U-87MG cell - 731253, 731257 3.4.17.21 U-87MG cell the level of glutamate carboxypeptidase II protein (GCPII) is regulated by valproic acid, a histone deacetylase (HDAC) inhibitor, through acetylation of lysine residue in the GCPII protein in human astrocytes, U-87MG 752648 3.4.17.21 ventral nerve cord - 669932